Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ocular Therapeutix, Inc.
  6. News
  7. Summary
    OCUL   US67576A1007

OCULAR THERAPEUTIX, INC.

(OCUL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ocular Therapeutix : HC Wainwright Adjusts Ocular Therapeutix's Price Target to $18 from $17, Keeps Buy Rating

10/12/2021 | 10:57am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
All news about OCULAR THERAPEUTIX, INC.
05/11Berenberg Bank Cuts Price Target on Ocular Therapeutix to $21 From $23, Maintains Buy R..
MT
05/10Ocular therapeutix reports first quarter 2022 financial results and business update
AQ
05/10HC Wainwright Adjusts Price Target on Ocular Therapeutix to $10 From $14, Reiterates Bu..
MT
05/10Piper Sandler Adjusts Price Target on Ocular Therapeutix to $16 From $20, Reiterates Ov..
MT
05/09OCULAR THERAPEUTIX : Q1 Earnings Snapshot
AQ
05/09TRANSCRIPT : Ocular Therapeutix, Inc., Q1 2022 Earnings Call, May 09, 2022
CI
05/09OCULAR THERAPEUTIX, INC Management's Discussion and Analysis of Financial Condition an..
AQ
05/09Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q1 Revenue $13.2M, vs. Street Est of $13..
MT
05/09Ocular Therapeutix, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/09Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Upd..
BU
More news
Analyst Recommendations on OCULAR THERAPEUTIX, INC.
More recommendations
Financials (USD)
Sales 2022 60,4 M - -
Net income 2022 -71,2 M - -
Net cash 2022 48,0 M - -
P/E ratio 2022 -3,61x
Yield 2022 -
Capitalization 245 M 245 M -
EV / Sales 2022 3,26x
EV / Sales 2023 2,30x
Nbr of Employees 228
Free-Float 99,4%
Chart OCULAR THERAPEUTIX, INC.
Duration : Period :
Ocular Therapeutix, Inc. Technical Analysis Chart | OCUL | US67576A1007 | MarketScreener
Technical analysis trends OCULAR THERAPEUTIX, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,19 $
Average target price 17,71 $
Spread / Average Target 455%
EPS Revisions
Managers and Directors
Antony Mattessich President, Chief Executive Officer & Director
Donald Notman Chief Financial Officer
Charles M. Warden Chairman
Peter Jarrett Chief Scientific Officer
Michael H. Goldstein Chief Medical Officer & Ophthalmology President
Sector and Competitors
1st jan.Capi. (M$)
OCULAR THERAPEUTIX, INC.-54.23%245
JOHNSON & JOHNSON5.86%476 521
PFIZER, INC.-8.70%302 483
ELI LILLY AND COMPANY17.11%291 184
ROCHE HOLDING AG-13.00%281 098
ABBVIE INC.10.78%265 067